My watch list
my.chemeurope.com  

my.chemeurope.com

With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.

  • My watch list
  • My saved searches
  • My saved topics
  • My newsletter
Register free of charge
Login  
eng  
DeutschEnglishFrançaisEspañol

Cinacalcet



Cinacalcet
Systematic (IUPAC) name
N-[(1R)-1-(1-naphthyl)ethyl]-3-
[3-(trifluoromethyl)phenyl]propan-1-amine
Identifiers
CAS number 226256-56-0
ATC code H05BX01
PubChem 156419
DrugBank APRD00872
Chemical data
Formula C22H22F3N 
Mol. mass 357.412 g/mol
Pharmacokinetic data
Bioavailability 20 to 25%
Increases if taken with food
Protein binding 93 to 97%
Metabolism Hepatic (CYP3A4-, CYP2D6- and CYP1A2-mediated)
Half life 30 to 40 hours
Excretion Renal (80%) and fecal (15%)
Therapeutic considerations
Licence data

EU US

Pregnancy cat.

B3(AU) C(US)

Legal status

℞ Prescription only

Routes Oral

Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure.[1]

References

  1. ^ Torres PU (2006). "Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease". Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 16 (3): 253-8. doi:10.1053/j.jrn.2006.04.010. PMID 16825031.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cinacalcet". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE